https://scholars.lib.ntu.edu.tw/handle/123456789/487345
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | Hour T.-C. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | CHAO-YUAN HUANG | en_US |
dc.contributor.author | KUO-HOW HUANG | en_US |
dc.contributor.author | Chen J. | en_US |
dc.contributor.author | YEONG-SHIAU PU | en_US |
dc.creator | Pu Y.-S.;Chen J.;Huang K.-H.;Huang C.-Y.;Cheng A.-L.;Hour T.-C.;CHIH-HUNG HSU;Lin C.-C. | - |
dc.date.accessioned | 2020-04-28T07:25:31Z | - |
dc.date.available | 2020-04-28T07:25:31Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 1078-1439 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247618891&doi=10.1016%2fj.urolonc.2006.06.002&partnerID=40&md5=eb8ce55d30310a86764bd450b76489e9 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/487345 | - |
dc.description.abstract | Purpose: Paclitaxel and 5-fluorouracil have been used to treat hormone-refractory prostate cancer with some success. In vitro data suggest that the combined cytotoxicity may be sequence dependent. Thus, we explored the combined effects of the 2 agents, both in vitro and in vivo. Patients and Methods: The combined cytotoxicity of paclitaxel and 5-fluorouracil, and the possible schedule dependence were studied in vitro using PC-3 and DU145 cells and the microculture tetrazolium assay. There were 23 patients with hormone-refractory prostate cancer treated with the regimen T-HDFL: paclitaxel 90 mg/m2 intravenously 1 hour on days 1 and 8; 5-fluorouracil 2000 mg/m2; and leucovorin 300 mg/m2 intravenous 24-hour infusion on days 2 and 9, which repeated every 21 days. The allowed percentage of bone marrow irradiation was 50%. Results: Significant synergistic cytotoxicity was seen only when paclitaxel was given 24 hours before 5-fluorouracil. With the T-HDFL regimen, 11 (52%) of the 21 evaluable patients had ?50% reduction of prostate-specific antigen, lasting for 6 weeks. Of the 7 patients with measurable disease, 2 had a partial response. Median overall survival was 14.1 months. Grade III/IV leukopenia occurred in 2 patients. There was no treatment-related death. Toxicities were well tolerated. Conclusions: The combined cytotoxicity of paclitaxel and 5-fluorouracil is schedule dependent. It is feasible to administer weekly paclitaxel and high-dose 5-fluorouracil infusions in patients with hormone-refractory prostate cancer. Our findings may serve as an important rationale for future trial design. ? 2007 Elsevier Inc. All rights reserved. | - |
dc.relation.ispartof | Urologic Oncology: Seminars and Original Investigations | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | analgesic agent; betamethasone; fluorouracil; folinic acid; paclitaxel; tetrazolium; adult; aged; alopecia; anemia; article; bone marrow; bone metastasis; cancer pain; cancer survival; cell culture; clinical trial; controlled clinical trial; controlled study; cytotoxicity; demography; diarrhea; drug antagonism; drug dose reduction; drug exposure; drug potentiation; drug tolerability; drug withdrawal; febrile neutropenia; hand foot syndrome; human; human cell; infection; irradiation; leukopenia; liver metastasis; liver toxicity; lymph node metastasis; male; multiple cycle treatment; nausea; nephrotoxicity; neurotoxicity; phase 2 clinical trial; priority journal; prostate cancer; stomatitis; thrombocytopenia; treatment response; vomiting; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | - |
dc.title | Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.urolonc.2006.06.002 | - |
dc.identifier.pmid | 17483017 | - |
dc.identifier.scopus | 2-s2.0-34247618891 | - |
dc.relation.pages | 207-213 | - |
dc.relation.journalvolume | 25 | - |
dc.relation.journalissue | 3 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Urology-NTUH | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Urology-NTUH | - |
crisitem.author.dept | Surgical Oncology-NTUCC | - |
crisitem.author.dept | Urology | - |
crisitem.author.dept | Urology-NTUH | - |
crisitem.author.dept | Surgical Oncology-NTUCC | - |
crisitem.author.dept | Urology-NTUHBP | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.orcid | 0000-0002-9322-6062 | - |
crisitem.author.orcid | 0000-0002-0989-0578 | - |
crisitem.author.orcid | 0000-0002-2859-3966 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | NTU BioMedical Park Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。